ViewRay

ViewRay, Inc. designs, manufactures and markets magnetic resonance imaging (MRI) system. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

ViewRay (VRAY) delivered earnings and revenue surprises of -6.67% and 2.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) Reports Q4 Loss, Tops Revenue Estimates

CLEVELAND, Feb. 24, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2021. Full Year 2021 Highlights Total revenue of $70.1 million primarily from ten revenue units, compared to 2020 revenue of approximately $57.0 million, primarily from nine revenue units, including two system upgrades.

ViewRay Announces Fourth Quarter and Full Year 2021 Results

ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ViewRay (VRAY) Expected to Beat Earnings Estimates: Should You Buy?

ViewRay Inc (NASDAQ: VRAY) has announced interim data from the single-center Phase 3 MIRAGE trial comparing MRIdian MRI-guided vs. CT-guided SBRT for localized prostate cancer.

ViewRay's MRIdian MRI-Guided Imaging System Signal Superiority For Localized Prostate Cancer

CLEVELAND, Feb. 15, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that interim data from the single center Phase III randomized MIRAGE trial, led by UCLA, comparing MRIdian MRI-guided vs. CT-guided SBRT for localized prostate cancer, will be featured at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, held February 17-19 in San Francisco.

Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

CLEVELAND, Feb. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2021 financial results. ViewRay will hold a conference call to discuss results on Thursday, February 24, 2022 at 4:30 p.m.

ViewRay Announces Conference Call for Fourth Quarter and Full Year 2021 Financial Results to be Held After Market on February 24, 2022

CLEVELAND, Feb. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Zach Stassen, Chief Financial Officer, and Paul Strong VP, Clinical Affairs, will participate in a virtual fireside chat at 3:00 p.m.

ViewRay® to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

CLEVELAND, Feb. 9, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University Hospital Halle (Saale) in Germany has purchased a MRIdian MRI-guided radiation therapy system for installation at the University Hospital´s Krukenberg Cancer Center, the academic provider of cancer services in Southern Saxony-Anhalt with specialized treatment drawing patients from adjacent states and nationally. The Department of Radiation Oncology at University Hospital Halle (Saale), chaired by Prof.

University Hospital Halle (Saale) Selects ViewRay's MRIdian® System to Broaden Advanced Radiation Therapy Treatment Services

CLEVELAND, Jan. 25, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the B. Riley Securities Oncology Conference.

ViewRay® to Participate in the B. Riley Securities Oncology Conference

AvePoint

Compass

TRACON Pharmaceuticals

Vacasa

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Scorching-Hot Stocks Trading Under $10 With Big-Time Upside Potential

CLEVELAND, Jan. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2021. The preliminary results have not been audited and are subject to change.

ViewRay Announces Preliminary Fourth Quarter and Full Year 2021 Results

The consensus price target hints at a 38.4% upside potential for ViewRay (VRAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 38% Upside in ViewRay (VRAY): Here's What You Should Know

CLEVELAND, Dec. 23, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the 40th Annual J.P. Morgan Healthcare Conference.

ViewRay to Participate in the 40th Annual J.P. Morgan Healthcare Conference

CLEVELAND, Dec. 15, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company received FDA 510(k) clearance for its next generation of MRI-guided radiation therapy features, focused on enhancing on-table adaptive workflow and expanding clinical utility. MRIdian A3i includes a suite of new features to streamline on-table adaptive workflow and provide the potential to reduce treatment times, along with a new brain treatment package expanding clinical utility into cranial stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT).

ViewRay Receives 510(k) Clearance on Next Generation of MRIdian MRI-Guided Radiation Therapy Features

CLEVELAND, Dec. 7, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Northside Hospital in Georgia has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy treatment services at its Northside Hospital Cancer Institute in Atlanta. Northside Hospital Cancer Institute is the largest and most comprehensive cancer network in Georgia.

Northside Hospital Chooses MRIdian System to Expand Advanced Radiation Therapy Treatment Services

CLEVELAND, Nov. 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced, in recognition of Pancreatic Cancer Awareness Month, more than 2,300 pancreatic cancer patients have been treated with MRIdian at 46 centers around the world. ViewRay would like to recognize the global clinical teams providing options for patients who otherwise may not have been offered treatment.

ViewRay Announces MRIdian MR-Guided Radiation Therapy Surpasses 2,300 Pancreatic Cancer Patients Treated Worldwide

CLEVELAND, Nov. 23, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the closing of an additional 1,875,000 shares of common stock following the exercise in full of the underwriters' option to purchase additional shares in connection with its recently completed public offering of 12,500,000 shares of common stock, for additional gross proceeds of $10.5 million for total gross proceeds of $80.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.  All of the shares sold in the offering were sold by ViewRay.

ViewRay Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in connection with Public Offering of Common Stock

CLEVELAND, Nov. 19, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 12,500,000 shares of common stock at a price to the public of $5.60 per share, for gross proceeds of approximately $70.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.  All of the shares sold in the offering were sold by ViewRay.

ViewRay Announces Closing of Public Offering of Common Stock

CLEVELAND, Nov. 16, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of shares of its common stock.  In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock at the public offering price, less the underwriting discounts and commissions.

ViewRay Announces Proposed Public Offering of Common Stock

ViewRay, Inc.'s (VRAY) CEO Scott Drake on Q3 2021 Results - Earnings Call Transcript

CLEVELAND, Nov. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2021.  Third Quarter 2021 Highlights Received seven new orders for MRIdian systems totaling $39.4 million, compared to four new orders totaling $23.4 million in the third quarter of 2020.

ViewRay Reports Third Quarter 2021 Results

ViewRay (NASDAQ:VRAY) is set to give its latest quarterly earnings report on Thursday, 2021-11-04. Here's what investors need to know before the announcement.

ViewRay's Earnings: A Preview

CHICAGO, Oct. 28, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the results of a multi-center study of 148 inoperable pancreatic cancer patients treated with MRIdian SMART (MR-guided stereotactic adaptive radiation therapy) were presented as part of the Annual Meeting of the American Society for Radiation Oncology (ASTRO), the world's largest radiation oncology society, held October 24-27, 2021 in Chicago. The results, presented on October 27 by Michael Chuong, M.D.

New Outcomes Data Demonstrating Prolonged Survival for Inoperable Pancreatic Cancer Patients Presented at Leading Radiation Oncology Meeting

CLEVELAND, Oct. 25, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Helsinki University Hospital has purchased a MRIdian® System to offer patients MR-guided radiation therapy at the Comprehensive Cancer Center in the new Bridge Hospital. The Comprehensive Cancer Center is Finland's largest and most versatile cancer treatment center.

Helsinki University Hospital Selects MRIdian® System for Installation at Comprehensive Cancer Center

CLEVELAND, Oct. 22, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Baptist Health South Florida will acquire  a second MRIdian MR-guided radiation therapy system, joining other leading institutions from around the globe investing in multiple MRIdian systems. Baptist Health is expanding its MRIdian MR-guided radiation therapy services at Lynn Cancer Institute, part of Baptist Health South Florida.

News for ViewRay Stock (VRAY)